C
CTC Bio Inc
KOSDAQ:060590
CTC Bio Inc
KOSDAQ:060590
Price:
7 980 KRW
-0.62%
Market Closed
Updated:
Jun 10, 2024
Section:
Relative Value
The Relative Value of one CTC Bio Inc stock under the Base Case scenario is 7 390.8 KRW. Compared to the current market price of 7 980 KRW, CTC Bio Inc is Overvalued by 7%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
7 390.8
KRW
Overvaluation 7%
C
Valuation Multiples
Multiples Across Competitors
Competitors Multiples
CTC Bio Inc Competitors
CTC Bio Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| KR |
C
|
CTC Bio Inc
KOSDAQ:060590
|
190.8B KRW | 1.4 | -13.5 | 449.1 | -40.1 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
815.9B USD | 22.7 | 132.9 | 64.9 | 73.9 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4.4T DKK | 18 | 49.4 | 36.8 | 40.3 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
351.9B USD | 4.1 | 9.1 | 11.3 | 14.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
329.7B USD | 5.4 | 143 | 35.6 | 58.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
195.3B GBP | 5.2 | 39.3 | 175.3 | 279.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
191B CHF | 3.3 | 16.6 | 9.4 | 11.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
184.2B CHF | 3.5 | 11.7 | 8.9 | 13 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
159.2B USD | 2.9 | -515.3 | 12.6 | 20.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
